Less common effects: Nausea or mild stomach discomfort
STEP 5 trial participants who continued through the plateau maintained their weight loss at 104 weeks
CagriSema is composed of the GLP-1 RA semaglutide and the long-acting insulin analog cagrilintide, and can be administered subcutaneously once a week.117 Beinaglutide Beinaglutide was the first original drug approved for the treatment of obesity in China and the third GLP-1 class reduction drug approved worldwide, and it represents a new treatment option for overweight and obese patients.67,118,119 Beinaglutide, a recombinant human GLP-1 (rhGLP-1) polypeptide, exhibits a remarkable resemblance to human GLP-1(7-36), with nearly 100% homology.120 This innovative compound demonstrates dose-dependent efficacy in regulating glycemic control, suppressing appetite, delaying gastric emptying, and facilitating weight reduction.121 Consequently, beinaglutide holds significant promise for advancing research in the areas of overweight/obesity and nonalcoholic steatohepatitis (NASH).67,122 Beinaglutide is a natural human GLP-1(7-36)-NH2 expressed in Escherichia coli
Loomba R, Chalasani N (2015) The hierarchical model of NAFLD: prognostic significance of histologic features in NASH
Additionally, newer created medications in this class have GIP (glucose-dependent insulinotropic polypeptide), which also affects insulin levels and blood sugar just as GLP-1
These drugs were designed for long-term use, so manufacturers havent provided formal instructions for stopping
